Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors

Journal of Ocular Pharmacology and Therapeutics

Volumn 14, Issue 2, 1998, Pages 169-180

  Jacot, Jörge L ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; GALACTOSE; IMIRESTAT; RISARESTAT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA SENSIBILITY; DIABETES MELLITUS; DIETARY INTAKE; DRUG EFFECT; ENZYME INHIBITION; GALACTOSEMIA; KERATOPATHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; TOPICAL DRUG ADMINISTRATION;

EID: 0031980073     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1998.14.169     Document Type: Article

References (48)

1. Schwartz, D.E. Corneal sensitivity in diabetics. Arch. Ophthalmol. 91:174-178, 1974.
2. Friend, J. and Thoft, R.A. The diabetic cornea. Int. J. Ophthalmol. Clin. 24:111-123, 1984.
3. Schultz, R.O., Van Hörn, D.L., Peters, M.A., Kiewin, K.M., and Schütten W.H. Diabetic keratopathy. Trans AM Ophthalmol. Soc. 79:180-199, 1981.
4. Hyndiuk, R., Kazarian, E., Schultz, R.O., and Seideman, S. Neurotrophic corneal ulcers in diabetes mellitus. Arch. Ophthalmol. 95:2193-2196, 1977.
5. Perry, H.D., Foulks, G.N., Thoft, R.A., and Tolentino, F.L. Corneal complications after closed vitrectomy through the pars plana. Arch. Ophthalmol. 96:1401-1403, 1978.
6. Campos, M, Hertzog, L., Garbus, J., and McDonnell, P. Corneal sensitivity after photorefractive keratectomy. Am. J. Ophthalmol. 114:51-54, 1992.
7. Cogan, D.G., Kinoshita, J.H., Kador, P.P., Robison, W.G. Jr., Datiles, M.B., Cobo, L.M., and Kupfer, C. Aldose reductase and complications of diabetes. Ann. Intern. Med. 101:82-91, 1984.
8. Brightbill, F.S., Meyers, F.L., and Bresnick, G.H. Postvitrectomy keratopathy. Am. J. Ophthalmol. 85:651-655, 1978.
9. Faulborn, J., Conway, B.P., and Machemer, R. Surgical complications of pars plana vitreous surgery. Ophthalmology 85:116-125, 1978.
10. Foulks, G.N., Thoft, R.A., Perry, H.D., and Tolentino, F.L. Factors related to corneal epithelial complications after closed vitrectomy in diabetes. Arch. Ophthalmol. 97:1076-1088, 1979.
11. Kinoshita, J.H., Kador, P., and Datiles, M. Aldose reductase in diabetic cataracts. JAMA. 246: 257-261, 1981.
12. Simard-Duquesne, N. and Dvornik, D. Galactitol accumulation and irreversible lens opacities in galactosemic rats. Invest. Ophthalmol. Vis. Sei. 12:82-83, 1973.
13. Simard-Duquesne, N., Greselin, E., Gonzalez, R., Dvornik, D. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat (42048). Proc. Soc. Exp. Biol.Med. 178:599-605, 1985.
14. Fukushi, S., Merola, L.O., and Kinoshita, J.H. Altering the course of cataracts in diabetic rats. Invest. Ophthalmol. Vis. Sci. 19:313-315, 1980.
15. Robison, W.G. Jr., Kador, P.P., and Kinoshita, J.H. Retinal capillaries: Basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science (USA). 221: 1177-1179,1983.
16. Robison, W.G. Jr., Kador, P., Akagi, Y., Kinoshita, J.H., Gonzalez, R., and Dvornik, D. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes. 35:295-299, 1986.
17. Robison, W.G. Jr., Nagata, M., Laver, N., Hohman, T.C., and Kinoshita, J.H. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest. Ophthalmol. Vis. Sci. 30: 2285-2292, 1989.
18. Robison, W.G. Jr., Tillis, T.N., Laver, N., and Kinoshita ,J.H. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp. Eye Res. 50:355-366, 1990.
19. Robison, W.G. Jr., and Laver, N.M. Ocular lesions in animal models of human diabetes. In Lessons from Animal Diabetes IV. Shafrir, E., ed. Great Britain: Smith-Gordon, 1993, pp. 145-163.
20. Frank, R. N., Keirn, R. J., Kennedy, A., and Frank, K. W. Galactose-induced retinal capillary basement membrane thickening: Prevention by Sorbinil. Invest. Ophthalmol. Vis. Sei. 24:1519-1524, 1983.
21. Fukushi, S., Merola, L.O., Tanaka, M., et al. Reepithelialization of denuded corneas in diabetic rats. Exp. Eye Res. 31, 611-621, 1980.
22. Datiles, M., Kador, P.P., Fukui, H.N., Hu, T., and Kinoshita, J.H. Corneal re-epithelialization in galactosemic rats. Invest. Ophthalmol. Vis. Sei. 24:563-569, 1983.
23. Fukushi, S. Corneal epitheliopathy in diabetes. In Polyol Pathway and Its Role in Diabetic Complications. Sakamoto, N., Kinoshita, J.H., Kador, P.P., and Hotta, N., eds New York: Elsevier, 1988, pp. 217-230.
24. Kinoshita, J.H., Fukushi, S., Kador, P., and Merola, L.O. Aldose reductase in diabetic complications of the eye. Metabolism. 28:462-469, 1979.
25. Awata, T., Sogo, S., and Yamamoto, Y. Effects of aldose reductase inhibitor,CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats. Jpn. J. Ophthalmol. 30:245-250, 1986.
26. Hosotani, H., Ohashi, Y., Kinoshita, S., Matsumoto, T., and Awata, T. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Curr. Eye Res. 15:1005-1007, 1996.
27. Hosotani, H., Tano, Y., Tamada, R., Ohashi, Y., Mano, T., Umemoto, M., Maeda, N., Fukuda, M., and Manabe, R. Treatment of diabetic keratopathy with a topical aldose reductase inhibitor. Folia Ophthalmol. Jpn. 37:1359-1365, 1986.
28. Hosotani, H., Ohashi, Y., Yamada, M., and Tsubota, K. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am. J. Ophthalmol. 119:288-294, 1995.
29. Kador, PF. The role of aldose reductase in the development of diabetic complications. Medicinal Res. Rev., 8:3, 325-352, 1988.
30. Sato, S., Kador, PF, and Kinoshita, JH. International Symposium on Polyol Patlnvay, New York, Excerpta Medical International Congress Series, 760:72, 1988.
31. Awata, T., Matsuda, M., Ohashi, Y., and Fukuda, M. The effects of topical aldose reductase inhibitor on diabetic keratopathy: Current concepts of aldose reductase and its inhibitions. N. Sakamoto et al., Eisevier Science Publishers B.V. (Biomédical division), editors. 1990, pp. 149-156.
32. Ohashi, Y., Awata, T., Sogo, S., Ohira, M., Matsuda, M., Fukuda, M., and Manabe, R. Intraocular penetration of CT-112, and aldose reductase inhibitor, following topical instillation. J. Ocular Pharmacol. 5(4):325-328, 1989.
33. Robison, W.G. Jr., Laver, N., Jacot J.L., Glover, J.P. Basso, M.D., Blouin P., and Hohman, T.C. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest. Ophthalmol. Vis. Sei. 37(6): 1149-1156, 1996.
34. Millodot, M. Diurnal variation of corneal sensitivity. Br. J. Ophthalmol. 56:844-847, 1972.
35. Szerenyi, K., Sorken, K., Garbus, J., Lee, M., and McDonnell, P. Decrease in normal human comeal sensitivity with topical diclofenac sodium. Am. J. Ophthalmol. 118:312-315, 1994.
36. Cochet, P. and Bonnet, P. L'esthesie corneenne: sa mesure clinique/ses variations physiologiquespathologiques. La Clinique Ophtalmologique. 4:2-27, 1960.
37. Millodot, M. A review of research on the sensitivity of the cornea. Ophthal. Physiol. Opt. 4: 305-318, 1984.
38. Jacot, J.L., Lois, N., Glover, J.P., and Robison, W.G. Jr. Decreased central corneal sensitivity in the 50% galactose-fed rat model of diabetic ocular complications. VisionRes. 35:8181,1995 (abstract).
39. Strughold, H. The mechanical threshold of the cornea-reflex of the usual laboratory animals. Am. J. Physiol. 94:235-240, 1930.
40. Draeger, J. Modern aesthesiometry. Trans. Ophthal Soc. U.K. 99:247-250, 1979.
41. Boberg-Ans, J. Experience in clinical examination of corneal sensitivity. Br. J. Ophthalmol. 39:709726, 1955.
42. Dvornik, D., Millen, J., Hicks, D., Cayen, M., and Sredy, J. The pharmacokinetics of aldose reductase inhibitors.în Polyol Pathway and Its Role in Diabetic Complications. Sakamoto, N., Kinoshita, J.H., Kador, P.P., Hotta, N., eds., Amsterdam: Elsevier Science publisherB.V., 1988, pp. 61-71.
43. Simân, C.M., Naeser, P., and Eriksson, U.J. Increase lenticular aldose reductase activity and high incidence of congenital cataract in the offspring of diabetic rats. Acta Ophthalmol. 71:629-636, 1993.
44. Akagi, Y., Kador, P.P., Kuwabara, T., and Kinoshita, J.H. Aldose reductase localization in human retinal mural cells. Invest. Ophthalmol. Vis. Sei. 24:1516-1519, 1983.
45. Kern, T.S. and Engerman, R.L. Hexitol production by canine retinal microvessels. Invest. Ophthalmol Vis. Sei. 26:382-384, 1985.
46. Dvornik, D., Millen, J., Hicks, D.R., and Kraml, M. Tolrestat pharmacokinetics in rat peripheral nerve. J. Diab. Comp. 8:18-26, 1994.
47. Sima, A.A.F., Greene, D.A., Brown, M.B., Hohman, T.C., Hicks, D., Graepel, G.J., Bochenek, W.J., Beg, M., and Bonen, B. The Tolrestat Study Group. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J. Diab. Comp. 7:157-169, 1993.
48. Robison, W.G. Jr. Diabetic retinopathy:Ga!actose-fed rat model. Invest. Ophthalmol. Vis. Sei. 36(9): 1742-1744, 1995.